Journal of Clinical Medicine · 12 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes the epidemiology, pathogenesis, diagnostic approaches, and therapeutic strategies for uveitis in Behçet’s disease, a severe ocular complication. The central result is that biologic therapies, particularly anti-TNFα agents and interferons, have transformed the management and visual outcomes for this condition.
This narrative review synthesizes current knowledge on uveitis in Behçet’s disease (BD), a systemic vasculitis. The review outlines diagnostic tools like fluorescein angiography (FA) and scoring systems (e.g., BOS24) for monitoring relapse. Therapeutic strategies are summarized, including conventional immunosuppressants (azathioprine, cyclosporine) and biologics. Evidence from various studies indicates that anti-TNFα agents (infliximab, adalimumab) and interferon-alpha are effective for controlling intraocular inflammation and preventing relapses, with infliximab noted for a faster onset of action. The implications are that early, targeted therapy is crucial to limit visual sequelae.
